No official summary available for this bill.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 3598 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
2d Session
S. 3598
To provide for the periodic issuance of up-to-date clinical guidance on
addressing the health effects of per- and polyfluoroalkyl substances
(PFAS), and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
January 8 (legislative day, January 7), 2026
Mrs. Shaheen (for herself and Ms. Collins) introduced the following
bill; which was read twice and referred to the Committee on Health,
Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To provide for the periodic issuance of up-to-date clinical guidance on
addressing the health effects of per- and polyfluoroalkyl substances
(PFAS), and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Better Care for PFAS Patients Act of
2026''.
SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, RECOMMENDATIONS, AND GUIDANCE.
(a) Periodic Assessment and Recommendations.--
(1) Agreement.--The Director of the Agency for Toxic
Substances and Disease Registry (in this section referred to as
the ``Director'') shall enter into an agreement with the
National Academies of Sciences, Engineering, and Medicine (or
another appropriate entity if the National Academies declines
to enter into such agreement) under which the National
Academies or the other appropriate entity agrees--
(A) to assess the health effects of per- and
polyfluoroalkyl substances (in this section referred to
as ``PFAS'') that can be measured in human tissues;
(B) to formulate clinical recommendations on
addressing such health effects;
(C) not later than 2 years after the date of entry
into such agreement, to complete the initial assessment
under subparagraph (A) and formulate the initial
recommendations under subparagraph (B); and
(D) to update the most recent assessment and
recommendations under this paragraph--
(i) every 5 years; or
(ii) more frequently as determined
necessary by the Director based on an
assessment of the science.
(2) Consultation.--In carrying out the assessments under
paragraph (1), the National Academies of Sciences, Engineering,
and Medicine or other appropriate entity shall engage with PFAS
exposed communities and solicit input from members of such
communities regarding their experiences with PFAS exposure,
testing, and clinical follow-up.
(3) Timing of entry into agreement.--The Director shall
enter into the agreement required by paragraph (1) not later
than 60 days after the date of enactment of this Act.
(b) Up-to-Date Guidance.--Based on the results of the most recent
assessment and recommendations under subsection (a), the Director, in
consultation with the entity with which the Director enters into the
agreement under subsection (a), shall--
(1) not later than 5 years after the date of entry into the
agreement required by subsection (a)--
(A) issue up-to-date clinical guidance on
addressing the health effects of PFAS;
(B) post such guidance on the public website of the
Agency for Toxic Substances and Disease Registry; and
(C) disseminate such guidance to State and local
public health authorities and appropriate health care
professionals; and
(2) every 5 years thereafter, or more frequently as
determined necessary by the Director based on an assessment of
the science, issue, post, and disseminate up-to-date guidance
as described in paragraph (1).
<all>
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line